Synthetic cathinones found in abused 'bath salts' preparations are chiral molecules. Racemic 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinopentiophenone (α-PVP) are two common constituents of these preparations that have been reported to be highly effective reinforcers; however, the relative contribution of each enantiomer toward these effects has not been determined. Thus, male Sprague-Dawley rats were trained to respond for racemic MDPV or α-PVP (n = 9/drug), with full dose-response curves for the racemate and the S and R enantiomers of MDPV and α-PVP generated under a progressive ratio schedule of reinforcement. Racemic mixtures of both MDPV and α-PVP as well as each enantiomer maintained responding in a dose-dependent manner, with racemic MDPV and α-PVP being equipotent. The rank order of potency within each drug was S enantiomer > racemate ≫ R enantiomer. Although both enantiomers of α-PVP were as effective as racemic α-PVP, R-MDPV was a slightly less effective reinforcer than both S and racemic MDPV. The results of these studies provide clear evidence that both enantiomers of MDPV and α-PVP function as highly effective reinforcers and likely contribute toward the abuse-related effects of 'bath salts' preparations containing racemic MDPV and/or α-PVP. Behavioural Pharmacology 28:578-581
Introduction
Racemic mixtures of the synthetic cathinones 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinopentiophenone (α-PVP) are commonly identified in abused 'bath salts' preparations. MDPV and α-PVP are monoamine uptake inhibitors that are selective for the dopamine transporter (DAT) (Baumann et al., 2013; Simmler et al., 2013) . Both compounds have been classified by the Drug Enforcement Administration as Schedule I compounds (Drug Enforcement Administration, 2014) . Similar to other stimulant drugs of abuse, MDPV and α-PVP have been shown to stimulate locomotor activity, produce cocainelike discriminative stimulus effects, facilitate intracranial self-stimulation, and are readily self-administered (Fantegrossi et al., 2013; Watterson et al., 2014a Watterson et al., , 2014b Aarde et al., 2015; Kolanos et al., 2015; Collins et al., 2016; Gannon et al., 2016 Gannon et al., , 2017 Smith et al., 2016) .
MDPV and α-PVP are chiral molecules, each with two enantiomers (designated as 'R' and 'S'). Structurally, each enantiomer only differs from the other in its threedimensional absolute configuration around the chiral center. Pharmacologically, enantiomers can differ from one another in many ways including potency, activity, and mechanism of action. For MDPV, there is inconsistency in the literature with respect to the activity of R-MDPV. For instance, although both enantiomers of MDPV have been shown to inhibit DAT uptake and dose dependently increase cocaine-appropriate responding in mice trained to discriminate cocaine from saline (although S-MDPV is more potent than R-MDPV) (Kolanos et al., 2015; Gannon et al., 2016) , R-MDPV appears to lack cardiovascular effects (at doses ≤ 3 mg/kg) and fails to facilitate intracranial self-stimulation (at doses ≤ 10 mg/kg) (Kolanos et al., 2015; Schindler et al., 2016) . Although the inability of R-MDPV to facilitate intracranial self-stimulation suggests that it does not contribute toward the abuse-related effects of racemic MDPV, the reinforcing effects of each enantiomer of either MDPV or α-PVP have not been reported. Thus, the present study evaluated the self-administration of MDPV, α-PVP, and the R and S enantiomers of each drug under a progressive ratio (PR) schedule of reinforcement so that their relative reinforcing potency and effectiveness could be compared directly.
Methods

Subjects
Male Sprague-Dawley rats (275-300 g) obtained from Harlan (Indianapolis, Indiana, USA) were singly housed and maintained in a temperature-controlled and humidity-controlled environment on a 10/14-h dark/light cycle with free access to tap water and Purina rat chow.
All experimental procedures were conducted in accordance with the Institutional Animal Care and Use Committee of the University of Texas Health Science Center at San Antonio (San Antonio, Texas, USA) and the Eighth Edition of the Guide for Care and Use of Laboratory Animals (National Research Council, 2011) .
Surgery
Chronic indwelling catheters were implanted in the left femoral vein under isoflurane anesthesia as described previously (Gannon et al., 2017) . Penicillin G (60 000 U/rat; subcutaneously) was administered after surgery to prevent infection. All rats were allowed 5-7 days to recover before initiating experiments. Catheters were flushed daily before (0.2 ml saline) and after [0.5 ml heparinized saline (100 U/ml)] operant sessions.
Apparatus
Standard two-lever operant conditioning chambers (Med Associates, St Albans, Vermont, USA) situated inside sound-attenuating cubicles were used for all experiments. Three LED lights (red, green, and yellow) were located above each lever and a white houselight was located at the top center of the opposite wall. Drug was delivered using a variable-speed syringe pump through Tygon tubing connected to a stainless-steel fluid swivel and spring tether held in place by a counterbalanced arm.
Self-administration
Illumination of the yellow LED above the active lever (left or right; counterbalanced) signaled drug availability and served as the discriminative stimulus. Completion of the response requirement resulted in a drug infusion (0.1 ml/kg over ∼ 1 s) paired with the illumination of the houselight and all three lights above the active lever, and initiated a 5 s timeout. Responding during timeouts or on the inactive lever was recorded, but had no scheduled consequence. Rats were trained to respond under a fixed ratio 1 schedule of reinforcement for MDPV or α-PVP (0.032 mg/kg/infusion) during daily 90 min sessions. The response requirement increased to an fixed ratio of 5 before transitioning rats to a PR schedule of reinforcement, where they were maintained for the duration of the experiment. Under this schedule, the response requirements for each successive infusion incremented according to the following equation: ratio = (5e infusion # × 0.2 ) − 5. The maximum session duration was 12 h, but sessions were terminated if a ratio was not completed within 45 min (i.e. 45-min limited hold). Rats trained to respond for MDPV (n = 9) were used to evaluate MDPV (0.0032-0.178 mg/kg/ infusion), S-MDPV (0.001-0.178 mg/kg/infusion), and R-MDPV (0.1-3.2 mg/kg/infusion), whereas rats trained to respond for α-PVP (n = 9) were used to evaluate α-PVP (0.0032-0.32 mg/kg/infusion), S-α-PVP (0.001-0.32 mg/kg/ infusion), and R-α-PVP (0.1-3.2 mg/kg/infusion). The first dose evaluated was 0.032 mg/kg/infusion of the racemate, with all the remaining doses evaluated in a random order. Each dose was available for at least two consecutive sessions and until stability criteria ( 2 infusions from the previous session) were fulfilled. All doses for a particular drug were assessed before evaluating the next.
Drugs
Racemic MDPV and α-PVP were synthesized by Kenner Rice in the Laboratory of Medicinal Chemistry at the National Institute on Drug Abuse (Bethesda, Maryland, USA). The enantiomers of both MDPV and α-PVP were obtained by optical resolution of the racemate with the appropriate enantiomer of 2-bromotartranilic acid. The optical purity of each of the resolved enantiomers was determined by 400 MHz nuclear magnetic resonance after the addition of the chiral shift reagent 1-phenyl-2,2,2-trifluoroethanol. In all cases, no optical impurity was detected in any of the four resolved enantiomers. The limit of detection of this method was less than 1.0% as determined by the addition of known amounts of optical impurity. Thus, the optical purity of each of the enantiomers was more than 99%. Our data indicate that traces of optical impurity (< 1.0% if present at all) in these enantiomers would not influence R/S potency relationships. We have no evidence for any optical impurity in any of the enantiomers. All drugs were prepared fresh daily in 0.9% physiological saline to reduce the likelihood of racemization (Suzuki et al., 2015) .
Data analysis
Graphical presentations of all data show the mean SEM of the number of infusions obtained at each unit dose. Dose-response data were normalized to the dose condition that maintained the most infusions (i.e. the E max ) for each subject. Normalized dose-response curves were fitted using a linear regression of the data spanning the 20-80% effect levels to obtain ED 50 s for individual subjects. ED 50 values were considered statistically different between drugs when the 95% confidence intervals were nonoverlapping. One-way analyses of variance, followed by pairwise comparisons using the Holm-Sidak method were used to detect differences in effectiveness among the racemate, S enantiomer, and R enantiomer of MDPV or α-PVP. A Student's t-test was used to detect significant differences between the E max of MDPV and α-PVP. Prism 6 software (GraphPad Software Inc., La Jolla, California, USA) was used to generate figures and carry out statistical analyses.
Results
Progressive ratio dose-response curves for MDPV, α-PVP, and their enantiomers are shown in Fig. 1 ; ED 50 and E max values are presented in Table 1 . For MDPV, one-way analysis of variance showed a main effect of drug on the E max [F(2,16) = 19.81, P < 0.001], with the E max for R-MDPV being significantly lower than that for MDPV (P < 0.05); E max values for MDPV and S-MDPV were not significantly different. The E max for α-PVP was not significantly different from either S-α-PVP or R-α-PVP. Potency differences were also observed, with S-MDPV being 2.13 (1.58-2.68)-fold more potent than MDPV, which was 28.86 (20.53-37.18)-fold more potent than R-MDPV. Similarly, S-α-PVP was 2.05 (1.34-2.75)-fold more potent than α-PVP, which was 23.04 (16.72-29.37)-fold more potent than R-α-PVP. Comparisons between MDPV and α-PVP showed no differences in E max or potency between MDPV and α-PVP.
Discussion
Synthetic cathinone abuse is a worldwide public health concern, with racemic MDPV and α-PVP being two of the most widely abused synthetic cathinones in the USA. Racemic mixtures of MDPV or α-PVP are readily selfadministered by rats; however, the reinforcing effects of their enantiomers have not been assessed previously. Therefore, the present study used a PR schedule to quantify and compare the relative reinforcing potency and effectiveness of MDPV, α-PVP, and their respective enantiomers. The results of this study provide strong evidence that both enantiomers of MDPV and α-PVP are highly effective reinforcers and that both enantiomers likely contribute toward the maintenance of selfadministration by racemic mixtures of MDPV and α-PVP. Consistent with data reported by Aarde et al. (2015) , the present study indicates that MDPV and α-PVP are equipotent and equally effective reinforcers. For both MDPV and α-PVP, the rank order potency to maintain responding was S enantiomer > racemate ≫ R enantiomer and the S enantiomer was equally effective as the racemate. Analogous to previous reports with methamphetamine (Yokel and Pickens, 1973; Winger et al., 1994) , both enantiomers of MDPV and α-PVP were self-administered at high levels. Although the prototypical monoamine transporter inhibitor cocaine is known to have at least one inactive enantiomer (Katz et al., 1990) , direct comparisons with other inhibitors (e.g. MDPV or α-PVP) are complicated by the fact that cocaine has four chiral centers rather than one. It is noteworthy that although R-MDPV was found to be slightly less effective than either MDPV or S-MDPV, the level of responding maintained by R-MDPV is equivalent to that maintained by cocaine or Fig. 1 Dose-response curves for the self-administration of racemic (circles), S (squares), and R (triangles) MDPV (a) or α-PVP (b) under a progressive ratio schedule of reinforcement. Horizontal axis: SAL represents data obtained when saline was available for infusion, whereas numbers refer to the unit dose of each drug available for infusion expressed as mg/kg/infusion on a log scale. Vertical axis: (a) total infusions obtained during the session; (b) final ratio completed during the session. Symbols and error bars show mean SEM. MDPV, 3,4-methylenedioxypyrovalerone; α-PVP, α-pyrrolidinopentiophenone; SAL, saline. Group sizes: n = 9, MDPV; n = 9, α-PVP. CI, confidence interval; MDPV, 3,4-methylenedioxypyrovalerone; α-PVP, α-pyrrolidinopentiophenone. *P < 0.05 compared with all drugs (within group).
methamphetamine (Gannon et al., 2017) , suggesting that R-MDPV functions as a highly effective reinforcer.
As a racemic mixture is composed of~50% of each enantiomer, a two-fold potency difference between the most potent enantiomer and the racemate would account for the effects of the racemate (assuming that the more potent enantiomer is also fully effective). Indeed, S-MDPV and S-α-PVP were ∼ 2-fold more potent than (and equally effective as) MDPV and α-PVP. The selfadministration data presented here for MDPV and its enantiomers parallel the effects of MDPV and its enantiomers on DAT inhibition (Kolanos et al., 2015) , providing evidence that the reinforcing effects of MDPV and its enantiomers are related to their ability to inhibit DAT. A similar relationship likely exists for α-PVP and its enantiomers to inhibit DAT; however, these data have not been reported. Although these data suggest that the S enantiomers could account for the effects of MDPV and α-PVP, the levels of intake maintained by larger unit doses (≥0.032 mg/kg/infusion) of MDPV and α-PVP likely result in pharmacologically active levels of R-MDPV and R-α-PVP.
